These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17690487

  • 21. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis.
    Lau HK, Segev A, Hegele RA, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Haemost; 2003 Dec; 90(6):1187-91. PubMed ID: 14652655
    [Abstract] [Full Text] [Related]

  • 22. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 23. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA.
    Eur J Gastroenterol Hepatol; 2008 Sep 01; 20(9):912-6. PubMed ID: 18794606
    [Abstract] [Full Text] [Related]

  • 24. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun 01; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

  • 25. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb 01; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 26. Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm.
    Dubis J, Zuk N, Grendziak R, Zapotoczny N, Pfanhauser M, Witkiewicz W.
    Blood Coagul Fibrinolysis; 2014 Apr 01; 25(3):226-31. PubMed ID: 24378973
    [Abstract] [Full Text] [Related]

  • 27. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B, Kılıç N, Şimşek E, Dallar Y.
    J Clin Res Pediatr Endocrinol; 2012 Sep 01; 4(3):146-50. PubMed ID: 22985614
    [Abstract] [Full Text] [Related]

  • 28. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.
    Diabetes Res Clin Pract; 2006 Aug 01; 73(2):150-7. PubMed ID: 16458385
    [Abstract] [Full Text] [Related]

  • 29. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
    Paola Cellai A, Antonucci E, Alessandrello Liotta A, Fedi S, Marcucci R, Falciani M, Giglioli C, Abbate R, Prisco D.
    Thromb Res; 2006 Aug 01; 118(4):495-500. PubMed ID: 16318869
    [Abstract] [Full Text] [Related]

  • 30. Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
    Wada H, Nobori T, Watanabe R, Shiku H, Sakuragawa N.
    Turk J Haematol; 2002 Jun 05; 19(2):235-7. PubMed ID: 27264764
    [Abstract] [Full Text] [Related]

  • 31. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome.
    Aubert H, Frère C, Aillaud MF, Morange PE, Juhan-Vague I, Alessi MC.
    J Thromb Haemost; 2003 Apr 05; 1(4):791-7. PubMed ID: 12871417
    [Abstract] [Full Text] [Related]

  • 32. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 05; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 33. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications.
    Mazur P, Sokołowski G, Hubalewska-Dydejczyk A, Płaczkiewicz-Jankowska E, Undas A.
    Thromb Res; 2014 Aug 05; 134(2):510-7. PubMed ID: 24962680
    [Abstract] [Full Text] [Related]

  • 34. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 05; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 35. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M, Özbek M, Akbal E, Üreten K.
    Turk J Med Sci; 2019 Oct 24; 49(5):1381-1385. PubMed ID: 31549496
    [Abstract] [Full Text] [Related]

  • 36. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
    Ząbczyk M, Majewski J, Lelakowski J.
    Pol Arch Med Wewn; 2011 Nov 24; 121(11):400-7. PubMed ID: 22064373
    [Abstract] [Full Text] [Related]

  • 37. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov 24; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 38. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
    Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R.
    Gynecol Endocrinol; 2009 Feb 24; 25(2):110-6. PubMed ID: 19253106
    [Abstract] [Full Text] [Related]

  • 39. Thyroid dysfunction and fibrin network structure: a mechanism for increased thrombotic risk in hyperthyroid individuals.
    Hooper JM, Stuijver DJ, Orme SM, van Zaane B, Hess K, Gerdes VE, Phoenix F, Rice P, Smith KA, Alzahrani SH, Standeven KF, Ajjan RA.
    J Clin Endocrinol Metab; 2012 May 24; 97(5):1463-73. PubMed ID: 22378816
    [Abstract] [Full Text] [Related]

  • 40. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.
    Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC.
    Arterioscler Thromb Vasc Biol; 2000 Sep 24; 20(9):2156-61. PubMed ID: 10978263
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.